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Introduction
Measurament of MCVA is used for the diagnosis of
rheumatoid arthritis (RA), with similar sensitivity to but
higher specificity than rheumatoid factor. MCVA, have
been detected however in other diseases and also in
some healthy subjects.
Aim
To analyze the clinical features of patients positive for
anti-MCVA.
Patients and methods
Retrospective analysis of MCVA+ve patients detected
over a period of 3 years in a reference laboratory. 335
patients (32.5% men and 67.5% women) with anti-
MCVA ≥20U/ml fulfilled inclusion criteria.
Results
241/335 (71.9%) MCVA+ve patients had a rheumatic
condition; most (67%) of RA patients had values >100U/
ml and corresponded to seropositive cases with erosions.
Among vasculitis and connective tissue disease patients,
values were in the 20-60U/ml range. Only 7 of them, 4
lupus, two SS and one polyarteritis nodosa, had values
>60U/ml. Distribution in Still’s disease, palindromic
rheumatism and elderly-onset arthritis was similar. 73%
of non-filiated arthritis were 20-60U/ml. In the miscella-
neous group, psoriatic and microcrystalline arthritis,
polymyalgia rheumatica, sarcoidosis, arthritis associated
to inflammatory bowel disease and postinfectious arthri-
tis, 71.4% were <60U/ml. Only one case of polymyalgia
rheumatica and one of chondrocalcinosis was >100U/ml.
94/335 cases (28.1%) had no rheumatic disease. Of
them the six cases with MCVA >100U/ml were two
nephropaties, two lung diseases, one autoimmune hemo-
lytic anemia and one drepanocytosis.
Conclusions
Although anti-MCVA are considered highly specific for
RA, they are also detected in other rheumatic diseases
and in non rheumatic disorders. Values >60U/ml give a
higher positive predictive value (PPV) for RA diagnosis,
while a cut-off at >20U/ml, reduces PPV markedly.
Therefore, in patients with no articular symptoms,
values in the range 20-60U/ml should be considered
with caution.
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